MX2022001865A - Articulos y metodos para la administracion de agentes terapeuticos. - Google Patents

Articulos y metodos para la administracion de agentes terapeuticos.

Info

Publication number
MX2022001865A
MX2022001865A MX2022001865A MX2022001865A MX2022001865A MX 2022001865 A MX2022001865 A MX 2022001865A MX 2022001865 A MX2022001865 A MX 2022001865A MX 2022001865 A MX2022001865 A MX 2022001865A MX 2022001865 A MX2022001865 A MX 2022001865A
Authority
MX
Mexico
Prior art keywords
articles
methods
colon
therapeutic agent
therapeutic agents
Prior art date
Application number
MX2022001865A
Other languages
English (en)
Spanish (es)
Inventor
Carlo Giovanni Traverso
Robert S Langer
Joshua Korzenik
Christoph Winfried Johannes Steiger
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Publication of MX2022001865A publication Critical patent/MX2022001865A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2022001865A 2019-08-12 2020-08-12 Articulos y metodos para la administracion de agentes terapeuticos. MX2022001865A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962885450P 2019-08-12 2019-08-12
PCT/US2020/045987 WO2021030474A1 (en) 2019-08-12 2020-08-12 Articles and methods for administration of therapeutic agents

Publications (1)

Publication Number Publication Date
MX2022001865A true MX2022001865A (es) 2022-03-11

Family

ID=74568588

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001865A MX2022001865A (es) 2019-08-12 2020-08-12 Articulos y metodos para la administracion de agentes terapeuticos.

Country Status (11)

Country Link
US (2) US20210046011A1 (https=)
EP (1) EP4013401A4 (https=)
JP (1) JP2022544239A (https=)
KR (1) KR20220046623A (https=)
CN (1) CN114340615A (https=)
AU (1) AU2020330542A1 (https=)
BR (1) BR112022001645A2 (https=)
CA (1) CA3148226A1 (https=)
IL (1) IL290427A (https=)
MX (1) MX2022001865A (https=)
WO (1) WO2021030474A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202200019725A1 (it) 2022-09-26 2024-03-26 Bilayer Therapeutics Inc Forme e composizioni del chenodeossicolato di sodio
IT202200006161A1 (it) 2022-03-29 2023-09-29 Bilayer Therapeutics Inc Forms and compositions of sodium chenodeoxycholate

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68769A (en) * 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
US5472710A (en) 1988-04-16 1995-12-05 Schwarz Pharma Ag Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture
GB8812490D0 (en) 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
IT1230576B (it) 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
IL98087A (en) 1990-05-04 1996-11-14 Perio Prod Ltd Preparation for dispensing drugs in the colon
US5156850A (en) 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
IT1245889B (it) 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche per uso orale gastroresistenti contenenti sali di acidi biliari.
IT1245891B (it) 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche a rilascio controllato per uso orale gastroresistenti contenenti acidi biliari e loro sali.
IT1260505B (it) 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
US5914132A (en) 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5651983A (en) 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
JP3725539B2 (ja) 1993-02-26 2005-12-14 大正製薬株式会社 ビサコジル剤形
US5656290A (en) 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5843479A (en) 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
IT1265074B1 (it) * 1993-05-18 1996-10-30 Istituto Biochimico Italiano Composizione farmaceutica a lento rilascio contenente come sostanza attiva un acido biliare
US5514663A (en) 1993-10-19 1996-05-07 The Procter & Gamble Company Senna dosage form
JP3725542B2 (ja) 1993-10-19 2005-12-14 大正製薬株式会社 ピコサルフェート剤形
US5637319A (en) 1995-03-01 1997-06-10 Takada; Kanji Controlled-release preparations
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5763435A (en) 1995-11-21 1998-06-09 Children's Hospital Medical Center Sulfate conjugates of ursodeoxycholic acid, and their beneficial use in inflammatory disorders
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US6231888B1 (en) 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
US5846983A (en) 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
CA2294988C (en) 1997-07-01 2015-11-24 Isis Pharmaceuticals Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US6074689A (en) 1998-03-10 2000-06-13 Immucell Corporation Colonic delivery of protein or peptide compositions
US6096731A (en) 1998-06-24 2000-08-01 Institute For Drug Research, Inc. Method for preventing tissue damage associated with graft-versus-host or host-versus-graft disease following transplantation
WO2000016784A1 (en) 1998-09-21 2000-03-30 Amato Pharmaceutical Products, Ltd. Oral drug delivery system for enhancing the bioavailability of activated glycyrrhetin
US6326364B1 (en) 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
SE9901387D0 (sv) 1999-04-19 1999-04-19 Astra Ab New pharmaceutical foromaulations
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
EP1095650A1 (en) 1999-10-29 2001-05-02 Universiteit Leiden Double phase time-controlled release system
US7070803B2 (en) 2000-03-31 2006-07-04 Nycomed Austria Gmbh Controlled release pharmaceutical composition for oral use containing midodrine and/or active metabolite, desglymidodrine
CN1141974C (zh) 2000-06-07 2004-03-17 张昊 结肠定位释放的口服生物制剂
US8263112B2 (en) 2000-11-20 2012-09-11 Sorbent Therapeutics, Inc. In vivo use of water absorbent polymers
US6444477B1 (en) 2000-11-28 2002-09-03 Pharmagene Laboratories Limited Assay method for detecting 5-HT2B antagonists
US20030124196A1 (en) * 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
US20030083286A1 (en) * 2001-08-22 2003-05-01 Ching-Leou Teng Bioadhesive compositions and methods for enhanced intestinal drug absorption
JP2003160496A (ja) * 2001-11-27 2003-06-03 Minofuaagen Seiyaku:Kk グリチルリチン経口投与剤
US9149439B2 (en) 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
WO2007019888A2 (en) 2005-08-12 2007-02-22 Ctg Pharma S.R.L. Therapeutic compositions containing mesalamine and a co-agent for treating colon diseases
US8080579B2 (en) 2005-10-03 2011-12-20 The Regents Of The University Of Michigan Compositions and methods for treatment of inflammatory bowel disease
US20080004237A1 (en) 2006-02-23 2008-01-03 Tam Joemy C Polysacchocride prodrug of 5-fluorouracil (5-FU) with enhanced target specificity for galectin-3 expressing cancers
JP2010502591A (ja) * 2006-09-04 2010-01-28 パナセア バイオテック リミテッド プログラム可能な浮揚性送達技術
US8273376B2 (en) 2006-11-17 2012-09-25 Da Volterra Colonic delivery of metallo-dependent enzymes
EP2143424A4 (en) 2007-03-26 2013-07-31 Teikoku Seiyaku Kk ORAL PHARMACEUTICAL PREPARATION FOR SPECIFIC DELIVERY TO THE COLON
ES2393814T3 (es) 2007-04-04 2012-12-28 Sigmoid Pharma Limited Una composición farmacéutica oral
US10242888B2 (en) 2007-04-27 2019-03-26 Applied Materials, Inc. Semiconductor processing apparatus with a ceramic-comprising surface which exhibits fracture toughness and halogen plasma resistance
WO2009038591A1 (en) 2007-09-17 2009-03-26 Yale University Bile salt colloids and methods of making and using thereof
WO2009048289A2 (en) 2007-10-10 2009-04-16 Hanall Pharmaceutical Company. Ltd Pharmaceutical composition for treating hepatitis c virus infection comprising hmg-coa reductase inhibitor and bile acid
US20090246301A1 (en) 2008-03-31 2009-10-01 Ehrenpreis Ben Z Method for treating irritable bowel syndrome and other functional gastrointestinal disorders
KR101018894B1 (ko) 2008-08-27 2011-03-04 근화제약주식회사 체내 흡수가 증진된 탈니플루메이트 함유 서방정
CA2744697C (en) 2008-11-26 2016-06-21 Satiogen Pharmaceuticals, Inc. Use of compositions comprising bile acids, salts, and mimics thereof for the treatment of obesity or diabetes
US20110268794A1 (en) 2009-01-09 2011-11-03 Camilleri Michael L Methods and materials for delivering bile acids
WO2012151252A2 (en) 2011-05-02 2012-11-08 Biokier, Inc. Composition and method for treatment of diabetes
KR20110120866A (ko) 2009-01-12 2011-11-04 바이오키어 인코포레이티드 당뇨병 치료 조성물 및 치료방법
US8717032B2 (en) 2009-01-28 2014-05-06 Telefonaktiebolaget L M Ericsson (Publ) Electronic circuit breaker and a method of providing protection switching
ES2530049T3 (es) 2009-05-18 2015-02-26 Sigmoid Pharma Limited Composición que comprende gotas de aceite
WO2012012902A1 (en) 2010-07-28 2012-02-02 Msi Methylation Sciences Inc. S-adenosylmethionine formulations with enhanced bioavailability
US20110027342A1 (en) 2009-07-28 2011-02-03 Msi Methylation Sciences, Inc. S-adenosylmethionine formulations with enhanced bioavailability
US9301938B2 (en) 2009-09-23 2016-04-05 Biokier, Inc. Composition and method for treatment of diabetes
WO2011075539A2 (en) 2009-12-18 2011-06-23 Satiogen Pharmaceuticals, Inc. Treatment of obesity or diabetes with bile acid sequestrants
ES2552657T3 (es) 2010-05-26 2015-12-01 Satiogen Pharmaceuticals, Inc. Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
DK2637646T3 (en) 2010-11-08 2016-08-29 Albireo Ab PHARMACEUTICAL COMBINATION CONTAINING AN IBAT inhibitor and a bile acid binder
EP2661266B1 (en) 2011-01-07 2020-09-16 Anji Pharma (US) LLC Chemosensory receptor ligand-based therapies
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
WO2012097155A1 (en) 2011-01-14 2012-07-19 Chiasma Inc. Improved pharmaceutical compositions for delivery of ferric iron compounds, and methods of use thereof
US20120276056A1 (en) 2011-04-26 2012-11-01 Wieslaw Janusz Bochenek Method for Use of Biologic Agents Including Live or Dormant Forms of Bacteria and other organisms in Treating Infections, Inflammation and Other Diseases of Distal Small Intestine and Large Intestine
EP2800562A2 (en) 2012-01-06 2014-11-12 Elcelyx Therapeutics, Inc. Compositions and methods for treating metabolic disorders
KR20190120430A (ko) 2012-01-06 2019-10-23 엘셀릭스 테라퓨틱스 인코포레이티드 바이구아나이드 조성물 및 대사 장애를 치료하는 방법
EP3187171B1 (en) * 2012-04-30 2024-09-25 Tillotts Pharma AG A delayed release drug formulation
US20150174076A1 (en) * 2012-06-14 2015-06-25 Entrega, Inc. Mucoadhesive devices for delivery of active agents
HK1210825A1 (en) 2012-07-11 2016-05-06 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US20140112985A1 (en) 2012-10-22 2014-04-24 Polonez Therapeutics Llc Method of prevention and treatment of clostridium difficile infection
WO2014070769A1 (en) * 2012-10-29 2014-05-08 The University Of North Carolina At Chapel Hill Methods and compositions for treating mucosal tissue disorders
AU2014239883B2 (en) * 2013-03-14 2019-01-17 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
JP6396992B2 (ja) 2013-04-05 2018-09-26 ヌメディー， インコーポレイテッド 消化器系疾患およびその他の疾患の処置
CN104739845A (zh) * 2013-12-26 2015-07-01 上海医学生命科学研究中心有限公司 鹅去氧胆酸及其用途
US10182993B2 (en) 2015-04-06 2019-01-22 Patheon Softgels Inc. Compositions for colonic delivery of drugs
US20180193621A1 (en) * 2015-06-30 2018-07-12 Entrega Inc. Device for oral delivery of active agents
US10864170B2 (en) 2015-09-04 2020-12-15 Yale University Polymeric bile acid nanocompositions targeting the pancreas and colon
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
CN108601739B (zh) 2016-02-09 2022-01-04 阿尔比里奥公司 考来烯胺丸剂及其制备方法
WO2017138878A1 (en) 2016-02-09 2017-08-17 Albireo Ab Oral cholestyramine formulation and use thereof
ES2874669T3 (es) 2016-02-09 2021-11-05 Albireo Ab Formulación oral de colestiramina y uso de la misma
CA3018589A1 (en) 2016-03-29 2017-10-05 Colonaryconcepts Llc Formulations for treating constipation
WO2018213204A1 (en) 2017-05-15 2018-11-22 Axial Biotherapeutics, Inc. Inhibitors of microbially induced amyloid
EP3664782B1 (en) 2017-08-09 2025-01-29 Albireo AB Cholestyramine pellets, oral cholestyramine formulations and medical use thereof
CN111032019B (zh) 2017-08-09 2022-07-05 阿尔比里奥公司 考来烯胺颗粒、口服考来烯胺制剂及其用途
US20210290593A1 (en) 2018-07-11 2021-09-23 Duke University Use of sustained-release 5-hydroxytryptophan in treating gastrointestinal disorders
US20200046758A1 (en) 2018-08-09 2020-02-13 Albireo Ab Oral cholestyramine formulation and use thereof
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US20200046757A1 (en) 2018-08-09 2020-02-13 Albireo Ab Cholestyramine pellets, oral cholestyramine formulations, and uses thereof
US11524029B2 (en) 2018-08-13 2022-12-13 Viscera Labs, Inc. Therapeutic composition and methods
EP3646857A1 (en) 2018-11-01 2020-05-06 Evonik Operations GmbH Colonic delivery system for microorganisms

Also Published As

Publication number Publication date
JP2022544239A (ja) 2022-10-17
CA3148226A1 (en) 2021-02-18
IL290427A (en) 2022-04-01
WO2021030474A1 (en) 2021-02-18
AU2020330542A1 (en) 2022-02-17
EP4013401A1 (en) 2022-06-22
KR20220046623A (ko) 2022-04-14
BR112022001645A2 (pt) 2022-05-03
US12171879B2 (en) 2024-12-24
EP4013401A4 (en) 2023-07-12
CN114340615A (zh) 2022-04-12
US20220202721A1 (en) 2022-06-30
US20210046011A1 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
CO2022002685A2 (es) Nanopartículas lipídicas mejoradas para el suministro de ácidos nucleicos
AR112480A1 (es) Composiciones de glp-1 y sus usos
CO2022013777A2 (es) Uso de agentes para el tratamiento de condiciones respiratorias
MX2020003415A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
NI201400072A (es) Compuestos de carbamato y preparación y uso de los mismos
CO2021000174A2 (es) Composiciones tópicas para el alivio del dolor
CL2019001658A1 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos.
CL2020000019A1 (es) Agentes de iarn para la inhibición de la expresión de alfa-enac y métodos de uso.
CL2020000491A1 (es) Métodos para aumentar y/o estabilizar la función cardiaca en pacientes con enfermedad de fabry.
MX2019013799A (es) Peptido novedoso y composicion farmaceutica para tratar una enfermedad ocular que comprende el mismo como un ingrediente farmaceutico activo.
MX2021005876A (es) Elacestrant en combinacion con abemaciclib en mujeres con cancer de mama.
MX2020004516A (es) Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas.
AR106364A1 (es) Derivados de insulina y sus usos médicos
MX2022001865A (es) Articulos y metodos para la administracion de agentes terapeuticos.
CL2018000002A1 (es) Agente terapéutico y método para tratar el síndrome de hunter.
CL2021003034A1 (es) Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton
MX2017005461A (es) Formulacion de buprenorfina inyectable.
PE20211199A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
ECSP14023048A (es) Agentes terapéuticos para administración subcutánea optimizados
AR123227A1 (es) Terapias combinadas para su uso en el tratamiento del cáncer
CL2019002527A1 (es) Compuestos de tipo imidazo[4,5-c]quinolin-2-ona deuterados y su uso en el tratamiento del cáncer.
MX2019015927A (es) Composiciones para administración de fármacos y métodos de uso de las mismas.
AR103415A1 (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2
MX2015014939A (es) Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension.
ES2525009T3 (es) Glucoproteínas que tienen propiedades de movilización de lípidos y usos terapéuticos de las mismas